Aller au contenu principal
Retour à l'annuaire
Rhumatologue

Docteur CLAUDE LAURENT BENHAMOU

📍 Paris 6e Arrondissement (75)HospitalierRPPS 10003780284
📊 Reconnaissance scientifique : 31/100📝 88 articles publiés📚 HAL (8)🎓 5 thèses dirigées

✨ Profil synthétique

IA · 04/05/2026

Le Docteur Claude Laurent Benhamou est un rhumatologue hospitalier à Paris, spécialisé dans la recherche sur la santé osseuse et l'ostéoporose. Avec un h-index de 25 et 111 publications, il a dirigé plusieurs thèses dans le domaine de la biologie ostéoarticulaire et de la biomécanique. Ses travaux de recherche couvrent également l'utilisation de l'intelligence artificielle en rhumatologie et la pharmacovigilance.

Expertises présumées

  • Ostéoporose
  • Santé osseuse
  • Imagerie médicale osseuse
  • Pharmacovigilance en rhumatologie
  • Thérapies anti-TNF
  • Essais cliniques en rhumatologie
  • Génétique des maladies osseuses

Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.

Diplômes

🎓 DES & spécialité ordinale

  • Rhumatologie (SM)

📚 CES (Certificat d'Études Spéciales)

  • CES Rhumatologie

🎓 Diplômes

  • DE Docteur en médecine

Source : Annuaire Santé ANS (FHIR Practitioner.qualification) · Mises à jour quotidiennes.

Direction de thèses

🎓 5 thèses dirigées

Source theses.fr — signal de direction d'équipe / statut PU-PH (à confirmer via le site universitaire).

Activité de recherche & publications

Source : bases de données publiques (OpenAlex, PubMed).

h-index

31

h articles cités ≥ h fois chacun. Un h de 31 = 31 publications avec 31+ citations.

Citations

2 888

Publications

88

i10-index

46

Thématiques principales

  • Bone health and osteoporosis research ×57
  • Bone health and treatments ×19
  • Bone and Joint Diseases ×15
  • Bone Metabolism and Diseases ×14
  • Body Composition Measurement Techniques ×7

Affiliations FR : Université d'Orléans · Centre hospitalier universitaire d'Orléans

Voir sur OpenAlex ↗

Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.

Bibliographie

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Localisation des cabinets

Adresses géocodées via la Base Adresse Nationale (api-adresse.data.gouv.fr). Précision indicative.

Lieux de consultation

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

📊 Comprendre le remboursement

Prendre rendez-vous & contact

🗓 Trouver sur Doctolib📇 Ajouter à mes contacts

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Top publications · les plus citées

  • 1
    Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy

    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2010

    📚 315 citations🎯 RCR 10.05Top 3% NIH🩺 Clinique🔓 Open Access📄 PDF gratuit ↗
    Lire l'abstract Crossref ↓

    Abstract Patients treated with bisphosphonates for osteoporosis may discontinue or require a switch to other therapies. Denosumab binds to RANKL and is a potent inhibitor of bone resorption that has been shown to increase bone mineral density (BMD) and decrease fracture risk in postmenopausal women with osteoporosis. This was a multicenter, international, randomized, double-blind, double-dummy study in 504 postmenopausal women ≥ 55 years of age with a BMD T-score of −2.0 or less and −4.0 or more who had been receiving alendronate therapy for at least 6 months. Subjects received open-label branded alendronate 70 mg once weekly for 1 month and then were randomly assigned to either continued weekly alendronate therapy or subcutaneous denosumab 60 mg every 6 months and were followed for 12 months. Changes in BMD and biochemical markers of bone turnover were evaluated. In subjects transitioning to denosumab, total hip BMD increased by 1.90% at month 12 compared with a 1.05% increase in subjects continuing on alendronate (p < .0001). Significantly greater BMD gains with denosumab compared with alendronate also were achieved at 12 months at the lumbar spine, femoral neck, and 1/3 radius (all p < .0125). Median serum CTX levels remained near baseline in the alendronate group and were significantly decreased versus alendronate (p < .0001) at all time points with denosumab. Adverse events and serious adverse events were balanced between groups. No clinical hypocalcemic adverse events were reported. Transition to denosumab produced greater increases in BMD at all measured skeletal sites and a greater reduction in bone turnover than did continued alendronate with a similar safety profile in both groups. Copyright © 2010 American Society for Bone and Mineral Research

  • 2
    Alcohol and bone: review of dose effects and mechanisms

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2012

    📚 244 citations🎯 RCR 9.68Top 3% NIH
  • 3
    Oxytocin controls differentiation of human mesenchymal stem cells and reverses osteoporosis

    Stem cells (Dayton, Ohio) · 2008

    📚 159 citations🎯 RCR 4.26Top 10% NIH
    Lire l'abstract Crossref ↓

    Abstract Osteoporosis constitutes a major worldwide public health burden characterized by enhanced skeletal fragility. Bone metabolism is the combination of bone resorption by osteoclasts and bone formation by osteoblasts. Whereas increase in bone resorption is considered as the main contributor of bone loss that may lead to osteoporosis, this loss is accompanied by increased bone marrow adiposity. Osteoblasts and adipocytes share the same precursor cell and an inverse relationship exists between the two lineages. Therefore, identifying signaling pathways that stimulate mesenchymal stem cells osteogenesis at the expense of adipogenesis is of major importance for developing new therapeutic treatments. For this purpose, we identified by transcriptomic analysis the oxytocin receptor pathway as a potential regulator of the osteoblast/adipocyte balance of human multipotent adipose-derived stem (hMADS) cells. Both oxytocin (OT) and carbetocin (a stable OT analogue) negatively modulate adipogenesis while promoting osteogenesis in both hMADS cells and human bone marrow mesenchymal stromal cells. Consistent with these observations, ovariectomized (OVX) mice and rats, which become osteoporotic and exhibit disequilibrium of this balance, have significant decreased OT levels compared to sham-operated controls. Subcutaneous OT injection reverses bone loss in OVX mice and reduces marrow adiposity. Clinically, plasma OT levels are significantly lower in postmenopausal women developing osteoporosis than in their healthy counterparts. Taken together, these results suggest that plasma OT levels represent a novel diagnostic marker for osteoporosis and that OT administration holds promise as a potential therapy for this disease. Disclosure of potential conflicts of interest is found at the end of this article.

Publications scientifiques (50) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Transversal35

▼

Ostéoporose4

▼

Pharmacovigilance4

▼

IA en rhumatologie2

▼

Anti-TNF1

▼

Essai clinique1

▼

Génétique1

▼
  • Genetic algorithm and image processing for osteoporosis diagnosis

    Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference · 2010 · Journal Article

    Jennane R, Almhdie-Imjabber A, Hambli R, Ucan ON, et al.

    📚 4 cit.

Revue générale1

▼
  • Alcohol and bone: review of dose effects and mechanisms

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2012 · Journal Article

    Maurel DB, Boisseau N, Benhamou CL, Jaffre C

    📚 244 cit.🎯 RCR 9.68🔬→🩺 Translationnel

Sjögren1

▼

Partager cette fiche

in LinkedIn🟢 WhatsApp✉ Email

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.